Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other financing activities: 2018-2025

  • Voyager Therapeutics' Other financing activities fell 32.08% to $434,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year decrease of 7.49%. This contributed to the annual value of $1.2 million for FY2024, which is 22.21% up from last year.
  • Per Voyager Therapeutics' latest filing, its Other financing activities stood at $434,000 for Q2 2025, which was down 32.08% from $639,000 recorded in Q2 2024.
  • In the past 5 years, Voyager Therapeutics' Other financing activities ranged from a high of $639,000 in Q2 2024 and a low of $313,000 during Q2 2022.
  • Moreover, its 3-year median value for Other financing activities was $434,000 (2025), whereas its average is $497,000.
  • Per our database at Business Quant, Voyager Therapeutics' Other financing activities plummeted by 46.03% in 2022 and then spiked by 52.87% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Other financing activities (Quarterly) stood at $580,000 in 2021, then plummeted by 46.03% to $313,000 in 2022, then spiked by 33.55% to $418,000 in 2023, then skyrocketed by 52.87% to $639,000 in 2024, then tumbled by 32.08% to $434,000 in 2025.
  • Its last three reported values are $434,000 in Q2 2025, $639,000 for Q2 2024, and $418,000 during Q2 2023.